German biotech firm BioNTech announced plans to invest up to £1 billion (approximately $1.33 billion) over the next decade to expand its research and development operations in collaboration

with the UK government.

The investment stems from a new grant agreement signed by BioNTech UK, a subsidiary of the company, building on a multi-year partnership first launched in January 2023.

As part of the original agreement, BioNTech committed to enrolling up to 10,000 patients in clinical trials for personalized cancer treatments by the end of 2030, while also increasing its presence in the UK.

The UK government will provide BioNTech with up to £129 million ($172 million) in grant funding over 10 years to support these efforts.

The funding will help establish two new R&D facilities, with the first set to open in Cambridge. Plans for the second center are currently underway. Photo by Epizentrum, Wikimedia commons.